Treating patients undergoing hip fracture surgery with the new synthetic agent fondaparinux (Arixtra®), a selective Factor Xa inhibitor, for four weeks compared to one week markedly reduces the incidence of thromboembolic complications from 35% to 1.4%, a reduction of 96%, according to findings presented today at the SICOT meeting in San Diego. The Penthifra Plus trial is the first study to evaluate the benefit of four weeks of prophylaxis of deep-vein thrombosis and pulmonary embolism following hip fracture surgery.
“The very high efficacy of fondaparinux prophylaxis given for four weeks in the Penthifra Plus study will induce a dramatic change of the DVT prevention procedures in orthopedic surgery. In my opinion, this level of treatment effect for patients is similar in magnitude to that experienced when antibiotic therapy was first introduced,” said Bengt Eriksson, MD, PhD, Orthopaedic Surgeon at Sahlgrenska University Hospital /Ostra, Goteborg, Sweden and lead Investigator of the study.
“After a short one week of therapy is given to these patients, one third of the patients still experienced a thromboembolic event during the following month. Our study shows that four weeks of prophylaxis with fondaparinux reduces these events very substantially. This significantly improves the management of patients undergoing surgery for hip fracture, where the risk remains very high for at least four weeks.”
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!